Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of "Secondary" Pharmaceutical Patents

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Kapczynski, Amy ^a   Park, Chan ^b   Sampat, Bhaven ^c  

^a YALE UNIVERSITY   (United States)

^b MEDICINES PATENT POOL   (Switzerland)

^c Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTER; PRODRUG; SODIUM CHLORIDE;

ANALYTIC METHOD; ARTICLE; CODING; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; EXPIRATION DATE; GOVERNMENT REGULATION; INFORMATION PROCESSING; JURISPRUDENCE; PATENT; STANDARD; UNITED STATES; VALIDITY;

EMPIRICAL RESEARCH; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS;

EID: 84870850733     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049470     Document Type: Article

References (29)

1. Cohen WM, Nelson R, Walsh K (2000) Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not). National Bureau of Economic Research, Working Paper No. 7552.
2. Levin RC, Klevorik AK, Nelson RR, Winter SG, (1987) Appropriating the Returns from Industrial Research and Development. Brookings Papers on Economic Activity 3: 783-831.
3. Mansfield E, (1986) Patents and Innovation: An Empirical Study. Management Science 32 (2):: 173-181.
4. Scherer FM, (2009) The Political Economy of Patent Policy Reform in the United States. Journal on Telecommunications & High Technology Law 7 (2):: 167-216.
5. Caves RE, Whinston M, Hurwitz M, (1991) Patent Expiration, Entry and Competition in the U.S. Pharmaceutical Industry. Brookings Papers on Economic Activity: Microeconomics 1991: 1-66.
6. European Commission (2009) Pharmaceutical Sector Inquiry: Final Report.
7. Burdon M, Sloper K, (2003) The Art of Using Secondary Patents to Improve Protection. Journal of Medical Marketing 3 (3):: 226-238.
8. Furrow ME, (2008) Pharmaceutical Patent Life-Cycle Management after KSR v. Teleflex. Food and Drug Law Journal 63 (1):: 275-320.
9. Grabowski H, Vernon J, (2000) Effective Patent Life in Pharmaceuticals. International Journal of Technology Management 19 (1/2):: 98-120.
10. Grubb PW, Thomsen PR (2010) Patents for Chemicals, Pharmaceuticals, and Biotechnology: Fundamentals of Global Law, Practice, and Strategy. Oxford University Press.
11. Hemphill CS, Sampat BN, (2011) When Do Generics Challenge Drug Patents? Journal of Empirical Legal Studies 8 (4):: 613-649.
12. Pammolli F, Magazzini L, Riccaboni M, (2011) The Productivity Crisis in Pharmaceutical R&D. Nature reviews, Drug Discovery 10 (6):: 428-38.
13. OECD (2004) Patents, Innovation and Economic Performance,.
14. Gorlin D, (2008) Staving Off Death: A Case Study of the Pharmaceutical Industry's Strategies to Protect Blockbuster Franchises. Food and Drug Law Journal 63 (4):: 823-64.
15. Cheng J, (2008) Note, An Antitrust Analysis of Product Hopping in the Pharmaceutical Industry. Columbia Law Review 108 (6):: 1471-1515.
16. Rathod S, (2010) Ever-Greening: A Status Check in Selected Countries,. 7: 227-242.
17. Correa C (2007) Guidelines for the Examination of Pharmaceutical Patents: Developing a Public Health Perspective, WHO-ICTSD-UNCTAD.
18. Jaffe A, Lerner J (2006) Innovation and Its Discontents: How Our Broken Patent System Is Endangering Innovation and Progress, and What to Do About It. Princeton University Press.
19. Federal Trade Commission (2002) Generic Drug Entry Prior to Patent Expiration: An FTC Study.
20. Eisenberg R, (2008) Pharma's Nonobvious Problem. Lewis & Clark Law Review 12 (2):: 375-430.
21. Kapczynski A, (2009) Harmonization and Its Discontents: A Case Study of TRIPS Implementation in India's Pharmaceutical Sector. California Law Review 97 (6):: 1571-1649.
22. Park C (2008) Defining the Concept of "New Chemical Entity" in the Drug Regulatory and Patentability Contexts. World Health Organization.
23. Agency for Healthcare Research and Quality (1996-2009) Medical Expenditure Panel Survey: Prescribed Medicines File. http://www.ahrq.gov/mepsweb/data_stats/more_info_download_data_files.jsp. Accessed 2012 September 29.
24. Hemphill S, Sampat BN, (2012) Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals. Journal of Health Economics 31 (2):: 327-339.
25. U.S. Food and Drug Administration, Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. Electronic version at: http://www.fda.gov/drugs/informationondrugs/ucm129689.htm. Accessed 2012 October 17.
26. USPTO. Cassis BIB DVD.
27. Amin T, Kesselheim AS, (2012) Secondary Patenting of Branded Pharmaceuticals: A ase Study of How Patents On Two Key HIV Drugs Could be Extended for Decades. Health Affairs 31 (10):: 2286-94.
28. Park C (2010) The Implementation of India's Patent Law: A Review of Patents Granted by the Indian Patent Office, in Five Years Into the Product Patent Regime: India's Response UNDP.
29. Pfizer Inc. v. Apotex, Inc., (Fed. Cir. 2006). 480 F.3d 1348.